Hydrogen Gas Inhalation Ameliorates Lung Injury After Hemorrhagic Shock and Resuscitation
Overview
Authors
Affiliations
Background: Hemorrhagic shock and resuscitation (HSR) is known to cause inflammatory reactions in the lung parenchyma and acute lung injury, increasing the risk of complications that can lead to death. Hydrogen gas has shown to inhibit the formation and eliminate reactive oxygen species (ROS), which are known to cause reperfusion injury. Hence, the purpose of this study was to investigate the protective effect of 2% inhaled hydrogen gas on post-HSR lung injury.
Methods: Rats weighing 300-500 g were divided into three groups: sham, HSR, and hydrogen (H)/HSR groups. In the latter two groups, HSR was induced via femoral vein cannulation. Gas containing 2% hydrogen gas was inhaled only by those in the H/HSR group. Lung tissue and abdominal aorta blood were obtained for histologic examination and arterial blood gas analyses, respectively. Neutrophil infiltration and proinflammatory mediators were also measured.
Results: PO was lower in the HSR and H/HSR groups than in the sham group. Blood lactate level was not significantly different between the sham and H/HSR groups, but it was significantly higher in the HSR group. Infiltration of inflammatory cells into the lung tissues was more frequent in the HSR group. Myeloperoxidase (MPO) activity was significantly different among the three groups (highest in the HSR group). All proinflammatory mediators, except IL-6, showed a significant difference among the three groups (highest in the HSR group).
Conclusions: Inhalation of 2% hydrogen gas after HSR minimized the extent of lung injury by decreasing MPO activity and reducing infiltration of inflammatory cells into lung tissue.
Involvement of CD44 and MAPK14-mediated ferroptosis in hemorrhagic shock.
Ye H, He S, Du Y, Wang Y, Hu Y, Zhao C Apoptosis. 2023; 29(1-2):154-168.
PMID: 37751106 DOI: 10.1007/s10495-023-01894-6.
H Inhibits the Formation of Neutrophil Extracellular Traps.
Shirakawa K, Kobayashi E, Ichihara G, Kitakata H, Katsumata Y, Sugai K JACC Basic Transl Sci. 2022; 7(2):146-161.
PMID: 35257042 PMC: 8897170. DOI: 10.1016/j.jacbts.2021.11.005.
Wang J, Cheng Q, Fang J, Ding H, Liu H, Fang X Antioxidants (Basel). 2021; 10(12).
PMID: 34943036 PMC: 8750042. DOI: 10.3390/antiox10121933.
Molecular Hydrogen: A Promising Adjunctive Strategy for the Treatment of the COVID-19.
Li Y, Wang Z, Lian N, Wang Y, Zheng W, Xie K Front Med (Lausanne). 2021; 8:671215.
PMID: 34746162 PMC: 8569706. DOI: 10.3389/fmed.2021.671215.
Hydrogen: A Novel Option in Human Disease Treatment.
Yang M, Dong Y, He Q, Zhu P, Zhuang Q, Shen J Oxid Med Cell Longev. 2020; 2020:8384742.
PMID: 32963703 PMC: 7495244. DOI: 10.1155/2020/8384742.